ID   U2OS
AC   CVCL_0042
AS   CVCL_L856
SY   U-2 OS; U-2OS; U-2-OS; U2-OS; U20-S; U20S; 2T
DR   BTO; BTO:0001938
DR   CLO; CLO_0001272
DR   CLO; CLO_0009454
DR   EFO; EFO_0002869
DR   MCCL; MCC:0000468
DR   CLDB; cl53
DR   CLDB; cl4579
DR   CLDB; cl4580
DR   CLDB; cl4581
DR   CLDB; cl7217
DR   4DN; 4DNSR3V9ST6H
DR   Abcam; ab263976
DR   Abcam; ab279979
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-96
DR   BCRC; 60187
DR   BCRJ; 0304
DR   BioGRID_ORCS_Cell_line; 265
DR   BioSample; SAMN03472549
DR   BioSample; SAMN03472766
DR   BioSample; SAMN10987914
DR   cancercelllines; CVCL_0042
DR   CCRID; 1101HUM-PUMC000028
DR   CCRID; 3101HUMSCSP5030
DR   CCRID; 3101HUMTCHu88
DR   CCRID; 4201HUM-CCTCC00626
DR   CCRID; 5301HUM-KCB09062YJ
DR   Cell_Model_Passport; SIDM01191
DR   ChEMBL-Cells; CHEMBL3307757
DR   ChEMBL-Targets; CHEMBL615023
DR   CLS; 300364
DR   Cosmic; 687934
DR   Cosmic; 755312
DR   Cosmic; 909776
DR   Cosmic; 931038
DR   Cosmic; 931909
DR   Cosmic; 1044081
DR   Cosmic; 1044268
DR   Cosmic; 1066238
DR   Cosmic; 1074397
DR   Cosmic; 1078392
DR   Cosmic; 1082493
DR   Cosmic; 1097758
DR   Cosmic; 1529905
DR   Cosmic; 1733128
DR   Cosmic; 2009542
DR   Cosmic; 2301583
DR   Cosmic; 2440477
DR   Cosmic; 2816207
DR   Cosmic-CLP; 909776
DR   DepMap; ACH-000364
DR   DSMZ; ACC-785
DR   DSMZCellDive; ACC-785
DR   ECACC; 92022711
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS200HLU
DR   ENCODE; ENCBS266AAA
DR   ENCODE; ENCBS953RZO
DR   GDSC; 909776
DR   GEO; GSE54820
DR   GEO; GSM170250
DR   GEO; GSM185160
DR   GEO; GSM185161
DR   GEO; GSM287989
DR   GEO; GSM287990
DR   GEO; GSM320831
DR   GEO; GSM827583
DR   GEO; GSM879223
DR   GEO; GSM887722
DR   GEO; GSM888816
DR   GEO; GSM1231597
DR   GEO; GSM1231598
DR   GEO; GSM1231599
DR   GEO; GSM1231600
DR   GEO; GSM1231601
DR   GEO; GSM1231602
DR   GEO; GSM1231603
DR   GEO; GSM1231604
DR   GEO; GSM1231605
DR   GEO; GSM1231606
DR   GEO; GSM1231607
DR   GEO; GSM1231608
DR   GEO; GSM1231609
DR   GEO; GSM1231610
DR   GEO; GSM1356565
DR   GEO; GSM1356566
DR   GEO; GSM1356567
DR   GEO; GSM1356568
DR   GEO; GSM1356569
DR   GEO; GSM1356570
DR   GEO; GSM1356571
DR   GEO; GSM1356572
DR   GEO; GSM1356573
DR   GEO; GSM1356574
DR   GEO; GSM1356575
DR   GEO; GSM1356576
DR   GEO; GSM1356577
DR   GEO; GSM1356578
DR   GEO; GSM1356579
DR   GEO; GSM1356580
DR   GEO; GSM1356581
DR   GEO; GSM1356582
DR   GEO; GSM1356583
DR   GEO; GSM1356584
DR   GEO; GSM1356585
DR   GEO; GSM1356586
DR   GEO; GSM1356587
DR   GEO; GSM1670557
DR   GEO; GSM1676324
DR   GEO; GSM1701657
DR   IARC_TP53; 27710
DR   ICLC; HTL11001
DR   KCB; KCB 200962YJ
DR   KCLB; 30096
DR   LiGeA; CCLE_160
DR   LINCS_LDP; LCL-1431
DR   Lonza; 676
DR   MetaboLights; MTBLS247
DR   MetaboLights; MTBLS292
DR   PharmacoDB; U2OS_1619_2019
DR   PRIDE; PRD000118
DR   PRIDE; PXD000262
DR   PRIDE; PXD000157
DR   PRIDE; PXD000589
DR   PRIDE; PXD000953
DR   PRIDE; PXD000954
DR   PRIDE; PXD001220
DR   PRIDE; PXD002073
DR   PRIDE; PXD002117
DR   PRIDE; PXD002395
DR   PRIDE; PXD003754
DR   PRIDE; PXD009668
DR   PRIDE; PXD017130
DR   PRIDE; PXD020622
DR   PRIDE; PXD024796
DR   PRIDE; PXD025890
DR   PRIDE; PXD028992
DR   PRIDE; PXD030166
DR   PRIDE; PXD030304
DR   PRIDE; PXD030644
DR   Progenetix; CVCL_0042
DR   PubChem_Cell_line; CVCL_0042
DR   TOKU-E; 3379
DR   Ubigene; YC-C030
DR   Wikidata; Q28473037
RX   PubMed=77569;
RX   PubMed=833871;
RX   PubMed=2233717;
RX   PubMed=2823272;
RX   PubMed=3518877;
RX   PubMed=6081590;
RX   PubMed=7017212;
RX   PubMed=8040301;
RX   PubMed=8275086;
RX   PubMed=8617485;
RX   PubMed=12645653;
RX   PubMed=15150091;
RX   PubMed=15736406;
RX   PubMed=17354236;
RX   PubMed=17981215;
RX   PubMed=18359981;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21519327;
RX   PubMed=22068332;
RX   PubMed=22278370;
RX   PubMed=22460905;
RX   PubMed=23144859;
RX   PubMed=23649806;
RX   PubMed=24136885;
RX   PubMed=24618588;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=25960936;
RX   PubMed=26351324;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29853780;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.phe-culturecollections.org.uk/media/167509/u2os-celllineprofile.pdf
WW   http://141.61.102.20/mxdb/project/show/9191407937500
WW   https://www.proteinatlas.org/learn/cellines
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=U2-OS
WW   https://micro.magnet.fsu.edu/primer/techniques/fluorescence/gallery/cells/u2/u2cells.html
WW   https://www.olympus-lifescience.com/de/microscope-resource/primer/techniques/fluorescence/gallery/cells/epithelialindex/
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/u/cell-lines-detail-92.html
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/U2OS_Farnham_protocol.pdf
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~36 hours (PubMed=21519327); ~25-30 hours (DSMZ=ACC-785).
CC   HLA typing: A*01,02; B*12,w40; C*w02 (PubMed=77569).
CC   HLA typing: A*02:01,32:01; B*44:02,44:02; C*05:01,07:04; DQB1*03:04,05:03; DRB1*04:05,04:05 (PubMed=25960936).
CC   HLA typing: A*02:01,32:01; B*44:02,44:02; C*05:01,07:04; DQB1*03:02,05:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (PubMed=23649806; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using proteomics.
CC   Genome ancestry: African=2.75%; Native American=0%; East Asian, North=5.19%; East Asian, South=0%; South Asian=0%; European, North=60.98%; European, South=31.08% (PubMed=30894373).
CC   Misspelling: U-205; Note=Occasionally.
CC   Misspelling: U205; Note=Occasionally.
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
ST   Source(s): ATCC; CLS; CCRID; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=19787792; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12,13 (CLS; DSMZ)
ST   CSF1PO: 13 (ATCC; CCRID; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200)
ST   D10S1248: 13,14
ST   D12S391: 19,20
ST   D13S317: 13
ST   D16S539: 11,12
ST   D18S51: 12,14 (CLS; DSMZ; Genomics_Center_BCF_Technion)
ST   D18S51: 14 (CCRID; PubMed=19787792; PubMed=25877200)
ST   D19S433: 15
ST   D1S1656: 16,17.3
ST   D21S11: 31
ST   D22S1045: 15,16
ST   D2S1338: 20,24
ST   D2S441: 10,14
ST   D3S1358: 16
ST   D5S818: 8,11 (CLS; DSMZ)
ST   D5S818: 11 (ATCC; CCRID; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=19787792; PubMed=25877200)
ST   D6S1043: 11
ST   D7S820: 11,12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB)
ST   D7S820: 12 (PubMed=25877200)
ST   D8S1179: 12,14
ST   FGA: 20
ST   Penta D: 9
ST   Penta E: 10,13 (Genomics_Center_BCF_Technion; PubMed=25877200)
ST   Penta E: 13 (DSMZ)
ST   SE33: 19
ST   TH01: 6,9.3
ST   TPOX: 11,12
ST   vWA: 14,18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990;
RA   Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M.,
RA   Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.;
RT   "p53 functions as a cell cycle control protein in osteosarcomas.";
RL   Mol. Cell. Biol. 10:5772-5781(1990).
//
RX   PubMed=2823272; DOI=10.1073/pnas.84.21.7716;
RA   Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.;
RT   "Rearrangement of the p53 gene in human osteogenic sarcomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6081590; DOI=10.1002/ijc.2910020505;
RA   Ponten J., Saksela E.;
RT   "Two established in vitro cell lines from human mesenchymal tumours.";
RL   Int. J. Cancer 2:434-447(1967).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=8040301; DOI=10.1172/JCI117360;
RA   Giovannini M., Biegel J.A., Serra M., Wang J.-Y., Wei Y.-L.H., Nycum L.,
RA   Emanuel B.S., Evans G.A.;
RT   "EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and
RT   primitive neuroectodermal tumors with variant translocations.";
RL   J. Clin. Invest. 94:489-496(1994).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X;
RA   Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D.,
RA   Lollini P.-L., Picci P., Bertoni F., Baldini N.;
RT   "Immunostaining of the p30/32MIC2 antigen and molecular detection of
RT   EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral
RT   neuroectodermal tumor.";
RL   Hum. Pathol. 27:408-416(1996).
//
RX   PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4;
RA   Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N.,
RA   Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J.,
RA   Poremba C.;
RT   "Chromosomal alterations in osteosarcoma cell lines revealed by
RT   comparative genomic hybridization and multicolor karyotyping.";
RL   Cancer Genet. Cytogenet. 140:145-152(2003).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=15736406;
RA   Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W.,
RA   Milz S.;
RT   "Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS
RT   in comparison to human osteoblasts.";
RL   Anticancer Res. 24:3743-3748(2004).
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003;
RA   Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J.,
RA   Squire J.A., Zielenska M.;
RT   "Identification of cryptic microaberrations in osteosarcoma by
RT   high-definition oligonucleotide array comparative genomic
RT   hybridization.";
RL   Cancer Genet. Cytogenet. 179:52-61(2007).
//
RX   PubMed=18359981;
RA   Niforou K.N., Anagnostopoulos A.K., Vougas K., Kittas C.,
RA   Gorgoulis V.G., Tsangaris G.T.;
RT   "The proteome profile of the human osteosarcoma U2OS cell line.";
RL   Cancer Genomics Proteomics 5:63-78(2008).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
//
RX   PubMed=22068332; DOI=10.1038/msb.2011.82;
RA   Beck M., Schmidt A., Malmstroem J., Claassen M., Ori A.,
RA   Szymborska A., Herzog F., Rinner O., Ellenberg J., Aebersold R.;
RT   "The quantitative proteome of a human cell line.";
RL   Mol. Syst. Biol. 7:549-549(2011).
//
RX   PubMed=22278370; DOI=10.1074/mcp.M111.014050;
RA   Geiger T., Wehner A., Schaab C., Cox J., Mann M.;
RT   "Comparative proteomic analysis of eleven common cell lines reveals
RT   ubiquitous but varying expression of most proteins.";
RL   Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23144859; DOI=10.1371/journal.pone.0048262;
RA   Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H.,
RA   Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E.,
RA   Myklebost O., Meza-Zepeda L.A.;
RT   "Integrative analysis reveals relationships of genetic and epigenetic
RT   alterations in osteosarcoma.";
RL   PLoS ONE 7:E48262-E48262(2012).
//
RX   PubMed=23649806; DOI=10.1083/jcb.201210031;
RA   Kleiblova P., Shaltiel I.A., Benada J., Sevcik J., Pechackova S.,
RA   Pohlreich P., Voest E.E., Dundr P., Bartek J., Kleibl Z., Medema R.H.,
RA   Macurek L.;
RT   "Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1
RT   checkpoint.";
RL   J. Cell Biol. 201:511-521(2013).
//
RX   PubMed=24136885; DOI=10.1002/pbc.24801;
RA   Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J.,
RA   Wang W.-L., Kleinerman E.S.;
RT   "Natural killer cell therapy and aerosol interleukin-2 for the
RT   treatment of osteosarcoma lung metastasis.";
RL   Pediatr. Blood Cancer 61:618-626(2014).
//
RX   PubMed=24618588; DOI=10.1371/journal.pone.0091433;
RA   Chernobrovkin A.L., Zubarev R.A.;
RT   "Detection of viral proteins in human cells lines by xeno-proteomics:
RT   elimination of the last valid excuse for not testing every cellular
RT   proteome dataset for viral proteins.";
RL   PLoS ONE 9:E91433-E91433(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29853780; DOI=10.1155/2018/3082526;
RA   Salawu A., Wright K., Al-Kathiri A., Wyld L., Reed M.W.R., Sisley K.;
RT   "Sister chromatid exchange and genomic instability in soft tissue
RT   sarcomas: potential implications for response to DNA-damaging
RT   treatments.";
RL   Sarcoma 2018:3082526.1-3082526.8(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//